The bisphosponates: Chemical characteristics, skeletal biological effects and extra-skeletal effects;I bisfosfonati: Caratteristiche chimiche, effetti biologici scheletrici ed effetti extra-scheletrici

Reumatismo

Volumn 57, Issue 3, 2005, Pages 142-153

  Corrado, A ^a   Cantatore, Francesco Paolo ^a,b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b NONE   (Italy)

Author keywords

Arthritis; Bisphosponates; Inflammation; Osteoarthritis; Osteoclasts

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; INCADRONIC ACID; PAMIDRONIC ACID; PYROPHOSPHATE; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHROPATHY; BONE METASTASIS; BONE REMODELING; CHRONIC DISEASE; DRUG EFFECT; DRUG STRUCTURE; DRUG USE; HUMAN; HYPERCALCEMIA; IMMUNOCOMPETENT CELL; MESENCHYME CELL; MYELOMA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; REVIEW;

EID: 26644436246     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Fleisch H, Maerki J, Russell RG. Effect of pyrophosphate on dissolution of hydroxyapatite and its possible importance in calcium homeostasis. Proc Soc Exp Biol Med 1966; 122: 317-20.
2. Schibler D, Russell RG, Fleisch H. Inhibition by pyrophosphate and polyphosphate of aortic calcification induced by vitamin D3 in rats. Clin Sci 1968; 35: 363-72.
3. Fleisch HA, Russell RG, Bisaz S, Muhlbauer RC, Williams DA. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1970; 1: 12-8.
4. Rosenblum IY, Black HE, Ferrell JF. The effects of various diphosphonates on a rat model of cardiac calciphylaxis. Calcif Tissue Res 1977; 23: 151-9.
5. Briner WW, Francis MD, Widder JS. The control of dental calculus in experimental animals. Int Dent J 1971; 21: 61-72.
6. Muchlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991; 9: 1003-11.
7. Reitsma PH, Bijvoet OL, Frijlink WB, Vismans FJ, van Breukelen FJ. Pharmacology of disodium (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate. Adv Exp Med Biol 1980; 128: 219-27.
8. Reitsma PH, Bijvoet OL, Verlinden-Ooms H, Wee-Pals LJ. Kinetic studies of bone and mineral metabolism during treatment with (3- amino-1- hydroxypropylidene)-1,1-bisphosphonate-(APD) in rats. Calcif Tissue Int 1980; 32: 145-57.
9. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 1983; 35: 87-99.
10. Jung A, Mermillod B, Schenk R, Courvoisier B, Burkhardt P, Epiney J, et al. [Treatment of 10 cases of symptomatic Paget's disease with etidronate (EHDP)]. Schweiz Med Wochenschr 1976; 106: 1667-73.
11. Flanagan AM, Chambers TJ. Dichloromethylenebisphosphonate (C12MBP) inhibits bone resorption through injury to osteoclasts that resorb C12MBP-coated bone. Bone Miner 1989; 6: 33-43.
12. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S. A possible mechanism of specific action of bisphosphonates on osteoosteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffler borders. Bone 1995; 17: 137-44.
13. Makkonen N, Hirvonen MR, Teravainen T, Savolainen K, Monkkonen J. Different effects of three bisphosphonates on nitric oxide production by raw 264 macrophage-like cells in vitro. J Pharmacol Exp Ther 1996; 277: 1097-102.
14. Marshall MJ, Holt I, Davie MV. Osteoclast recruitment in mice is stimulated by 83-amino-1-hydroxypropylidene)-1,1-bisphosphonate. Calcif Tissue Int 1993; 52: 21-5.
15. Vitte C, Fleisch H, Guenther HL. Bisphosphonate induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996; 137: 2324-33.
16. Chappard D, Alexandre C, Palle S, Vico L, Morukov BV, Rodinova SS, et al. Effects of a bisphosphonate (1-hydroxy ethylene-1,1-bisphosphonic acid) on osteoclast number durin prolonged bed rest in healthy humans. Metabolism 1989; 38: 822-5.
17. Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: interaction between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 1991; 49: 407-15.
18. Hughes DE, MacDonald BR, Russel RGG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term culture of human bone marrow. J Clin Invest 1989; 83: 1939-5.
19. Murakami N, Takahashi N, Udagawa N, Tanaka S, Nakamura I, Zhang D, et al. Tiludronate affects polarized osteoclasts but not unpolarized one. Bone Miner 1994; 25: S67.
20. Nussbaum SR, Warrell RP Jr, Rude R, Glusman J, Bilezikian JP, et al. Dose rsponse study od laendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol 1993; 14: 268-76.
21. Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, Jones SJ, et al. Osteoclast-like cell formation and its regulation bi osteotropic hormones in mouse marrow cultures. Endocrinology 1988; 122: 1373-82.
22. Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugai N, et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996; 18: 9-14.
23. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993; 91: 2004-11.
24. Vitte C, Fleisch H, Guenther HL. Osteoblasts mediate the bisphosphonate inhibition of bone resorption through synthesis of an osteoclast-inhibiting activity. J Bone Miner Res 1994; 9 (Suppl 1): S142.
25. Khokher MA, Dandona P. Diphosphonates inhibit human osteoblast secretion and proliferation. Metabolism 1989; 38: 184-7.
26. Klein B, Ben-Bassat H, Breuer E, Solomon V, Golomb G. Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors. J Cell Biochem 1998; 68: 186-94.
27. Garcìa-Moreno C, Serrano S, Nacher M, Farré M, Dìez A, Marinoso ML, et al. Effect of alendronate on cultured normal human osteoblasts. Bone 1998; 22: 233-9.
28. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G. Bisphosphonates stimulate formation of osteoblasts precursor and mineralized nodules in murine and human bone marrow culture in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 1998; 22: 455-61.
29. Plotkin LI, Weinstein RS, Parfitt AM, Robertson PK, Manalogas SC, Bellido T. Prevention of osteocyte and osteoblats apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104: 1363-74.
30. Khokher MA, Dandona P. Diphosphonates inhibit human osteoblast secretion and proliferation. Metabolism 1989; 38: 184-7.
31. Ohya K, Yamada S, Felix R, Fleisch H. Effect of bisphosphonates on prostagalandin synthesis by rat bone cells and mouse calvaria in culture. Clin Sci 1985; 69: 403-11.
32. 3-induced increase of osteocalcin in plasma of rats in vivo and in culture medium. Calcif Tissue Int 1988; 42: 248-54.
33. Giuliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 1998; 27: 38-41.
34. Lian JB, Stein GS, Canalis E, Robey PG, Boskey AD. Bone formation: osteoblast lineage cells, growth factors, matrix proteins, and the mineralization process. In: M.J. Favus (ed), Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Philadelphia: Lippincott Williams and Wilkins 1999; 14-29.
35. Rehinolz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, et al. Bisphosphonates directly regulate cell proliferation, differentiation and gene expression in human osteoblasts. Cancer Res 2000; 60: 6001-7.
36. Russel RGG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 97: 97-106.
37. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J, et al. Molecular mechanism of action of bisphosphonates. Bone 1999; 24: S73-S79.
38. Zallone A, Faccio R, Zambonin G. I bisfosfonati: gruppi di molecole con diversi effetti intracellulari e applicazioni cliniche. Update on Bisfosfonati 1999; 6: 3-5.
39. Marshall C. Protein prenylation: a mediator of protein-protein interactions. Science 1993; 259: 1865-6.
40. Zhang F, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Ann Rev Biochem 1996; 65: 241-69.
41. Flora L. Comparative antiinflammatory and bone protective effects of two bisphosphonates on rat adjuvant arthritis. Arthritis Rheum 1979; 22: 240-6.
42. Dunn CJ, Galinet LA, Wu H, Nugent RA, Schlachter ST, Strait ND, et al. Demonstration of novel anti-arthritic and anti-inflammatory effects of disphosphonates. J Pharmacol Exp Ther 1993; 226: 1691-8.
43. Ceponis A, Waris A, Mönkönnen J, Laasonen L, Hyttinen M, Solovieva SA, et al. Effects of low-dose, non.cytotoxix, itraarticular liposomal clodronate on development of erosions and proteoglican loss in established antigen-induced arthritis in rabbit. Arthritis Rheum 2001; 44: 1908-916.
44. Van Rooijen N, Sanders A, van den Berg TK. Apoptosis of macrophages induced by liposome-mediaed intracellular delivery of clodronate and propamidime. J Immunol Methods 1996; 193: 93-9.
45. Selander KS, Monkkonen J, Karhukorpi EK, Harkonen P, Hannuniemi R, Vaananen HK. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996; 50: 1127-38.
46. Makkonen N, Salmien A, Rogers MJ, Frith JC, Urtti A, Azhayeva E, et al. Contrasting effects od alendronate and clodronate on raw 264 macrophages: the role of a bisphosphonate metabolite. Eur J Pharm Sci 1999; 8: 109-18.
47. Monkkonen J, Health TD. The effects of liposome-incapsulated and free clodronate on the growth of macrophage-like cells in vitro: the role of calcium and iron. Calcif Tissue Int 1993; 53: 139-46.
48. Serretti R, Core P, Muti S, Salaffi F. Influence of dichloromethylene diphosphonate on reactive oxygen species production by human neutrophils. Rheumatol Int 1993; 13: 135-8.
49. van Lent PL, Holthuysen AE vRN, vam de Putte LB, van der Berg WB. Role of macrophage-like synovial lining cells in localization and expression of inflammation in type II collagen-induced arthritis. Scand J Rheumatol 1995; 101(Suppl): 83-9.
50. Hamma-koutbali Y, Di Benedetto M, Ledoux D, Oudar O, Leroux Y, Lecouvey M, et al. A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem Biophys Res Comm 2003; 24: 816-23.
51. Green JR, Clezardin P. Mechanisms of bisphosphonate effect on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 2002; 25(Suppl 1): S3-S9.
52. Heikkila P, Teronen O, Hirn MY, Sorsa T, Tervahartial T, Sal T, et al. Inhibition of matrix-metalloproteinase-14 in osteosarcoma cells by clodronate. J Surg Res 2003; 1: 45-52.
53. Breedveld FC, Trentham DE. Progress in the understanding of inducible models of chronic arthritis. Rheum Dis Clin 1987; 13: 531-44.
54. Storm G, Crommelin DJA. Liposomes: quo vadis? Pharm Sci Tech Today 1998; 1: 115-24.
55. Osterman T, Kippo K, Lauren L, Pasanen I, Hannuniemi R, Sellman R. A comparison of clodronate and indomathacin in the treatment of adjuvant arthritis. Inflamm Res 1997; 46: 79-85.
56. Osterman T, Kippo K, Laurén L, Hannuniemi R, Sellman R. Effect of clodronate on established adjuvant arthritis. Rheumatol Int 1994; 14: 139-47.
57. Pennanen N, Lapinjoki S, Urtti A, Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6, and TNF-alpha secretion from RAW 264 cells in vitro. Pharm Res 1995; 12: 916-22.
58. Kong AS, Shao J, Rappo R, Leibowitz M. Effects of disphosphonates an rat adjuvant arthritis. Int J Immunopharmacol 1982; 4: 311.
59. Van Lent P, van den Berselaar L, van den Hoek A, van de Ende M, Dijkstra CD, Van Rooijen N. Reversible depletion of synovial lining cells after intra-articular treatment with liposome-encapsulated dichlomethylene diphosphonate. Rheumatol Int 1993; 13: 21-30.
60. Redlich K, Hayer S, Maier A. Tumor Necrosis factor α-mediate joint destruction ins inhibited by targeting osteoclasts with protegerin. Arthritis Rheum 2002; 46: 785-92.
61. Markusse HM, Lafeber GJ, Breedveld FC. Bisphosphonate in collagen-induced arthritis. Rheumatol Int 1990; 9: 281-3.
62. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-α and RANK-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111: 821-31.
63. Cantatore FP, Acquista CA, Pipitone V. Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 1999; 26: 2318-23.
64. Van Offel JF, Schuerwegh AJ, Bridts CH, Bracke PG, Stevens WJ, De Clerck LS. Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis trated with low dose prednisolone and methotrexate. Clin Exp Rheum 2001; 19: 13-20.
65. Eggelmejer F, Papapoulos SE, Henk C, et al. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 1994; 21: 2016-20.
66. Maccagno A, Di Giorgio E, Roldan EJA, Caballero LE, Perez Lloret A. Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis. J Rheumatol 1994; 23: 211-4.
67. Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA. Clinical, biochemical and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989; 48: 396-9.
68. Maksymowych WP, Jhangri GS, Leclerq S, Skeith K, Yan A, Russel AS. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 1998; 25: 714-7.
69. Maksymowych WP, Jhangri GS, Fitzgerald AA, Leclerq S, Chiu P, Yah A, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002; 46: 766-73.
70. Maksymowych WP, Lambert R, Jhangri GS, Leclerq S, Chiu P, Wong B, et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001; 28: 144-55.
71. Ferracciol GF, Salaffi F, Carotti M, Cervini C, Baroli E. C12 MDP improves rheumatoid inflammation. In: 5th INWIN, Interscience World Conference of Inflammation, Antirheumatics, Analgesics, Immunomodulators, Geneva, Switzerland 1993; 25-28 Aprol 1993: abstract 208.
72. 2 microglobulin in rheumatoid arthritis. J Rheumatol 1996; 23: 1117-8.
73. Barrera P, Blom A, van Lent PLEM, van Bloois L, Beijnen JH, Van Rooijen N, et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum 2000; 43: 1951-9.
74. van Lent PL, Holthuysen AE, van den Bersselaar LA, van Rooijen N, Joosten LA, van de Loo FA, et al. Phagocitic lining cells determine local expression of inflammation in type II collagen-induced arthritis. Arthritis Rheum 1996; 39: 1545-55.
75. Thiebaud D, Sauty A, Burkhardt P, Leuenberger P, Sitzler L, Green JR, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997; 61: 386-92.
76. Harinck HI, Papapoulos SE, Blanksma HJ, Vermey P, Bijuoet OL II. Paget's disease of bone: early and late responses to three different with aminohydroxypropylidene bisphosphonate (APD). BMJ 1987; 295: 1301-5.
77. Wuster C, Schoter KH, Thiebaud D, Manegold C, Krahl D, Clemens MR, et al. Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia. Bone Miner 1993; 22: 77-85.
78. Gallacher SJ, Ralston SH, Patel U, Boyle IT. Side-effects of pamidronate. Lancet 1989; ii: 42-3.
79. Fenton AJ, Gutteridge DH, Kent GN, Price RI, Rettallak RW. Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responses. Clin Endocrinol 1991; 34: 197-204.
80. Schweitzer DH, Oostendorp-van de Ruit M, van der Pluijm G, Löwik CWGM, Papapoulos SE. Interleukin-6 and the acute-phase response during treatment of patients with Paget's disease with the nitrogen-cotaining bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J bone Min Res 1995; 10: 956-62.
81. Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, et al. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.Bone 1996; 18: 133-9.
82. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini F, Salvagno G, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987; 41: 326-31.
83. Cantrill JA, Andersn DC. Treatment of Paget's disease of bone. Clin Endocrinol 1990; 32: 507-18.
84. Pioli G, Hughes DE, Milan A, Aarden L, Meager A, Chapman K, et al. Bisphosphonate stimulate the production of cytokines by human peripheral blood mononuclear cells in vitro. Calcif Tissue Int 1990; 46 (suppl 2): A54.
85. Bijvoet OLM, Frijlink WB, Mulder H, van Osteroom AT. APD in Paget's disease of bone. Role of the mononuclear phagocyte system. Arthritis Rheum 1980; 23: 1193-204.
86. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducin skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488-93.
87. Endo Y, Nakamura M, Kikuchi T, Shinoda H, Takeda Y, Nitta Y, et al. Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increse macrophages, granulocytes and osteoclasts in vivo. Calcif Tissue Int 1993; 52: 248-54.
88. Pietschmann P, Stohlawetz P, Brosch S, Steiner G, Smolen JS, Peterlik M. The effect of alendronate con cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells. Calcif Tissue Int 1998; 63: 325-30.
89. Muehleman C, Green J, Williams JM, Kuettner KE, Thonar EJ, Sumner DR. The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. Osteoarthritis Cartilage 2002; 10: 226-33.
90. Podworny NV, Kandel RA, Renlund RC, Grynpas MD. Partial chondroprotective effect of Zolendronate in a rabbit model of inflammatory arthritis. J Rheumatol 1999; 26: 1972-82.
91. Evans CH, Mears DC. Binding of the bone-seeking agent 99mTc-1-hydroxyethilydene-1,1-diphosphonic acid to cartilage and collagen in vitro and its stimulation by Er3+ and low pH. Calcif Tissue Int 1980; 32: 91-4.
92. Evequoz V, Trechsel U, Fleish H. Effect of bisphosphonates on production of interleukin 1-like acticity by macrophages and its effect on rabbit chondrocytes. Bone 1985; 6: 439-44.
93. Guenther HL, Guenther HE, Fleisch H. The effects of 1-hydroxyethane-1,1- diphosphonate and dicloro-methane-diphosphonate on collagen synthesis by rabbit articular chondrocytes and rat bone cells. Biochem J 1981; 196: 293-301.
94. Edmonds-Alt X, Breliere JC, Roncucci R. Effects of 1-hydroxyethilene-1,1- diphosphonate and (chloro-4-phenyl)-thiomethylene bisphosphonic acid (SR 41319) on the mononuclear cell factor-mediated release of neutral proteinases by articular chindrocytes and synovial cells. Biochem Pharmacol 1985; 34: 4043-9.